Fasching PA, Brucker C, Decker T, Engel A, et al. Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study. Int J Cancer 2026 Mar 6. doi: 10.1002/ijc.70397.
PMID: 41792052